William Blair downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $19.71 yesterday.

Downgrades

Sarepta Therapeutics (SRPT) Sees Strong Mid-Day UpsideApril 22, 2016 12:03 PM RBC Sees Odds on Sarepta (SRPT) 9:1 AgainstApril 22, 2016 9:27 AM Wedbush Downgrades Sarepta Therapeutic (SRPT) to Neutral (Yesterday)April 22, 2016 7:24 AM Buy Sarepta Therapeutic (SRPT) on Sell-Off - Needham & CompanyApril 22, 2016 6:40 AM Sarepta (SRPT) PT Lowered to $23 at Baird as FDA Digs in for a Fight on EteplirsenApril 21, 2016 4:53 PM Oppenheimer Maintains Bullish View on Sarepta (SRPT) Despite Sell-Off on FDA Briefing DocumentsApril 21, 2016 1:20 PM Sarepta Therapeutics (SRPT) Sees Quick Sell-Off Following FDA Briefing DocsApril 21, 2016 8:08 AM Sarepta Therapeutics (SRPT) on watch as FDA briefing documents hitApril 21, 2016 8:00 AM